Ph.D., M.D., Managing Partner, Sutter Hill
Jeff Bird focuses on healthcare, including biotechnology and medical devices.
Recent Series A investments include Forty Seven Inc. (monoclonal antibody immuno-oncology therapies) and XIOS Therapeutics (small molecular immuno-oncology.) In the genomics space, Jeff is a co-investor with Illumina in Helix (consumer genomics marketplace) and GRAIL (cancer screening test). Jeff was CEO and an investor at Verinata Health (noninvasive prenatal diagnosis). He is currently a board member at Drais Pharmaceuticals, NuGen Technologies, Portola Pharmaceuticals, Restoration Robotics, and Threshold Pharmaceuticals. He also represents the firm’s investments in Acceleron Pharmaceuticals, Ameritox and Pacific Biosciences. Jeff was formerly a director at Horizon Pharma (HZNP), Akarx Inc., BARRX Medical, Inc., and Idun Pharmaceuticals. Jeff was previously Senior Vice President, Business Operations at Gilead Sciences. Jeff received a degree in Biological Sciences from Stanford in 1982, a Ph.D. in Cancer Biology in 1988 and a M.D. in 1992 from Stanford Medical School.